These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 10458773

  • 1. Selective amino acid substitutions of a subdominant Epstein-Barr virus LMP2-derived epitope increase HLA/peptide complex stability and immunogenicity: implications for immunotherapy of Epstein-Barr virus-associated malignancies.
    Micheletti F, Guerrini R, Formentin A, Canella A, Marastoni M, Bazzaro M, Tomatis R, Traniello S, Gavioli R.
    Eur J Immunol; 1999 Aug; 29(8):2579-89. PubMed ID: 10458773
    [Abstract] [Full Text] [Related]

  • 2. Design of dimeric peptides obtained from a subdominant Epstein-Barr virus LMP2-derived epitope.
    Marastoni M, Bazzaro M, Gavioli R, Micheletti F, Traniello S, Tomatis R.
    Eur J Med Chem; 2000 Jun; 35(6):593-8. PubMed ID: 10906411
    [Abstract] [Full Text] [Related]

  • 3. HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2.
    Lee SP, Thomas WA, Murray RJ, Khanim F, Kaur S, Young LS, Rowe M, Kurilla M, Rickinson AB.
    J Virol; 1993 Dec; 67(12):7428-35. PubMed ID: 7693972
    [Abstract] [Full Text] [Related]

  • 4. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
    Okugawa K, Itoh T, Kawashima I, Takesako K, Mazda O, Nukaya I, Yano Y, Yamamoto Y, Yamagishi H, Ueda Y.
    Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
    [Abstract] [Full Text] [Related]

  • 5. [Sequence analysis of the CTL epitopes in transmembrane region of latent membrane protein 2 of Epstein-Barr virus derived from nasopharyngeal carcinoma cells].
    Zhang NH, Zhang XS, Li J, Zhang RH, Gao YF, Zeng MS.
    Ai Zheng; 2006 May; 25(5):566-9. PubMed ID: 16687075
    [Abstract] [Full Text] [Related]

  • 6. Immediate-early transactivator Rta of Epstein-Barr virus (EBV) shows multiple epitopes recognized by EBV-specific cytotoxic T lymphocytes.
    Pepperl S, Benninger-Döring G, Modrow S, Wolf H, Jilg W.
    J Virol; 1998 Nov; 72(11):8644-9. PubMed ID: 9765404
    [Abstract] [Full Text] [Related]

  • 7. Three immunoproteasome-associated subunits cooperatively generate a cytotoxic T-lymphocyte epitope of Epstein-Barr virus LMP2A by overcoming specific structures resistant to epitope liberation.
    Ito Y, Kondo E, Demachi-Okamura A, Akatsuka Y, Tsujimura K, Tanimoto M, Morishima Y, Takahashi T, Kuzushima K.
    J Virol; 2006 Jan; 80(2):883-90. PubMed ID: 16378990
    [Abstract] [Full Text] [Related]

  • 8. Activation of epitope-specific memory cytotoxic T lymphocyte responses by synthetic peptides.
    Reali E, Guerrini R, Giori B, Borghi M, Marastoni M, Tomatis R, Traniello S, Masucci MG, Gavioli R.
    Clin Exp Immunol; 1996 Aug; 105(2):369-75. PubMed ID: 8706347
    [Abstract] [Full Text] [Related]

  • 9. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies.
    Gottschalk S, Edwards OL, Sili U, Huls MH, Goltsova T, Davis AR, Heslop HE, Rooney CM.
    Blood; 2003 Mar 01; 101(5):1905-12. PubMed ID: 12411306
    [Abstract] [Full Text] [Related]

  • 10. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma.
    Duraiswamy J, Sherritt M, Thomson S, Tellam J, Cooper L, Connolly G, Bharadwaj M, Khanna R.
    Blood; 2003 Apr 15; 101(8):3150-6. PubMed ID: 12468425
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
    Tischer S, Dieks D, Sukdolak C, Bunse C, Figueiredo C, Immenschuh S, Borchers S, Stripecke R, Maecker-Kolhoff B, Blasczyk R, Eiz-Vesper B.
    J Immunol Methods; 2014 Jun 15; 408():101-13. PubMed ID: 24877879
    [Abstract] [Full Text] [Related]

  • 12. Cytotoxic T lymphocyte epitope analogues containing cis- or trans-4-aminocyclohexanecarboxylic acid residues.
    Marastoni M, Bazzaro M, Micheletti F, Gavioli R, Tomatis R.
    Bioorg Med Chem; 2002 Sep 15; 10(9):3061-6. PubMed ID: 12110330
    [Abstract] [Full Text] [Related]

  • 13. HLA-A11-restricted epitope polymorphism among Epstein-Barr virus strains in the highly HLA-A11-positive Chinese population: incidence and immunogenicity of variant epitope sequences.
    Midgley RS, Bell AI, Yao QY, Croom-Carter D, Hislop AD, Whitney BM, Chan AT, Johnson PJ, Rickinson AB.
    J Virol; 2003 Nov 15; 77(21):11507-16. PubMed ID: 14557636
    [Abstract] [Full Text] [Related]

  • 14. Nonresponsiveness to an immunodominant Epstein-Barr virus-encoded cytotoxic T-lymphocyte epitope in nuclear antigen 3A: implications for vaccine strategies.
    Schmidt C, Burrows SR, Sculley TB, Moss DJ, Misko IS.
    Proc Natl Acad Sci U S A; 1991 Nov 01; 88(21):9478-82. PubMed ID: 1719531
    [Abstract] [Full Text] [Related]

  • 15. Cytotoxic T-lymphocyte responses to a polymorphic Epstein-Barr virus epitope identify healthy carriers with coresident viral strains.
    Brooks JM, Croom-Carter DS, Leese AM, Tierney RJ, Habeshaw G, Rickinson AB.
    J Virol; 2000 Feb 01; 74(4):1801-9. PubMed ID: 10644353
    [Abstract] [Full Text] [Related]

  • 16. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs.
    Gottschalk S, Ng CY, Perez M, Smith CA, Sample C, Brenner MK, Heslop HE, Rooney CM.
    Blood; 2001 Feb 15; 97(4):835-43. PubMed ID: 11159505
    [Abstract] [Full Text] [Related]

  • 17. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy.
    Lee SP, Tierney RJ, Thomas WA, Brooks JM, Rickinson AB.
    J Immunol; 1997 Apr 01; 158(7):3325-34. PubMed ID: 9120290
    [Abstract] [Full Text] [Related]

  • 18. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease.
    Bollard CM, Straathof KC, Huls MH, Leen A, Lacuesta K, Davis A, Gottschalk S, Brenner MK, Heslop HE, Rooney CM.
    J Immunother; 2004 Apr 01; 27(4):317-27. PubMed ID: 15235393
    [Abstract] [Full Text] [Related]

  • 19. The lifespan of major histocompatibility complex class I/peptide complexes determines the efficiency of cytotoxic T-lymphocyte responses.
    Micheletti F, Bazzaro M, Canella A, Marastoni M, Traniello S, Gavioli R.
    Immunology; 1999 Mar 01; 96(3):411-5. PubMed ID: 10233722
    [Abstract] [Full Text] [Related]

  • 20. Polymorphonuclear neutrophils pulsed with synthetic peptides efficiently activate memory cytotoxic T lymphocytes.
    Reali E, Guerrini R, Moretti S, Spisani S, Lanza F, Tomatis R, Traniello S, Gavioli R.
    J Leukoc Biol; 1996 Aug 01; 60(2):207-13. PubMed ID: 8773582
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.